Cargando…

Metabolic and cardiovascular benefits and risks of 4-hydroxy guanabenz hydrochloride: α(2)-adrenoceptor and trace amine-associated receptor 1 ligand

BACKGROUND: α(2)-adrenoceptor ligands have been investigated as potential therapeutic agents for the treatment of obesity. Our previous studies have shown that guanabenz reduces the body weight of obese rats, presumably through its anorectic action. This demonstrates an additional beneficial effect...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kotańska, Magdalena, Marcinkowska, Monika, Kuder, Kamil J., Walczak, Maria, Bednarski, Marek, Siwek, Agata, Kołaczkowski, Marcin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539439/ https://www.ncbi.nlm.nih.gov/pubmed/37624466 http://dx.doi.org/10.1007/s43440-023-00518-9

Ejemplares similares

Guanabenz—an old drug with a potential to decrease obesity
por: Kotańska, Magdalena, et al.
Publicado: (2022)

Metabolic benefits of 1-(3-(4-(o-tolyl)piperazin-1-yl)propyl)pyrrolidin-2-one: a non-selective α-adrenoceptor antagonist
por: Kotańska, Magdalena, et al.
Publicado: (2017)

Evaluation of Some Safety Parameters of Dual Histamine H(3) and Sigma-2 Receptor Ligands with Anti-Obesity Potential
por: Mika, Kamil, et al.
Publicado: (2023)

Synthesis and biological evaluation of N-arylpiperazine derivatives of 4,4-dimethylisoquinoline-1,3(2H,4H)-dione as potential antiplatelet agents
por: Marcinkowska, Monika, et al.
Publicado: (2018)

Dual Molecules Targeting 5-HT(6) and GABA-A Receptors as a New Approach to Combat Depression Associated with Neuroinflammation
por: Marcinkowska, Monika, et al.
Publicado: (2023)

Multifunctional Arylsulfone and Arylsulfonamide-Based Ligands with Prominent Mood-Modulating Activity and Benign Safety Profile, Targeting Neuropsychiatric Symptoms of Dementia
por: Marcinkowska, Monika, et al.
Publicado: (2021)

Idalopirdine, a selective 5-HT(6) receptor antagonist, reduces food intake and body weight in a model of excessive eating
por: Kotańska, Magdalena, et al.
Publicado: (2018)

Histamine H(3) Receptor Ligands—KSK-59 and KSK-73—Reduce Body Weight Gain in a Rat Model of Excessive Eating
por: Mika, Kamil, et al.
Publicado: (2021)

Chemically Homogenous Compounds with Antagonistic Properties at All α(1)-Adrenoceptor Subtypes but not β(1)-Adrenoceptor Attenuate Adrenaline-Induced Arrhythmia in Rats
por: Pytka, Karolina, et al.
Publicado: (2016)

H(3) histamine receptor antagonist pitolisant reverses some subchronic disturbances induced by olanzapine in mice
por: Dudek, Magdalena, et al.
Publicado: (2016)

Guanabenz modulates microglia and macrophages during demyelination
por: Thompson, Kaitlyn Koenig, et al.
Publicado: (2020)

Discovery of Potential, Dual-Active Histamine H(3) Receptor Ligands with Combined Antioxidant Properties
por: Kuder, Kamil J., et al.
Publicado: (2021)

Manifestations of Liver Impairment and the Effects of MH-76, a Non-Quinazoline α1-Adrenoceptor Antagonist, and Prazosin on Liver Tissue in Fructose-Induced Metabolic Syndrome
por: Kubacka, Monika, et al.
Publicado: (2023)

2-(4-Fluorophenyl)-1H-benzo[d]imidazole as a Promising Template for the Development of Metabolically Robust, α1β2γ2GABA-A Receptor-Positive Allosteric Modulators
por: Marcinkowska, Monika, et al.
Publicado: (2023)

A Comparison of the Anorectic Effect and Safety of the Alpha(2)-Adrenoceptor Ligands Guanfacine and Yohimbine in Rats with Diet-Induced Obesity
por: Dudek, Magdalena, et al.
Publicado: (2015)

Effect of Guanabenz on Rat AMD Models and Rabbit Choroidal Blood Flow
por: Shen, Yi, et al.
Publicado: (2011)

Guanabenz Interferes with ER Stress and Exerts Protective Effects in Cardiac Myocytes
por: Neuber, Christiane, et al.
Publicado: (2014)

Guanabenz Prevents d-Galactosamine/Lipopolysaccharide-Induced Liver Damage and Mortality
por: Perego, Jessica, et al.
Publicado: (2017)

Adrenoceptors: ligand-activated molecular dynamics
por: Matijssen, B, et al.
Publicado: (2008)

MH-76, a Novel Non-Quinazoline α(1)-Adrenoceptor Antagonist, but Not Prazosin Reduces Inflammation and Improves Insulin Signaling in Adipose Tissue of Fructose-Fed Rats
por: Kubacka, Monika, et al.
Publicado: (2021)

Synthesis and Pharmacological Evaluation of Novel Silodosin-Based Arylsulfonamide Derivatives as α(1A)/α(1D)-Adrenergic Receptor Antagonist with Potential Uroselective Profile
por: Canale, Vittorio, et al.
Publicado: (2018)

Antihypertensive Drug Guanabenz Is Active In Vivo against both Yeast and Mammalian Prions
por: Tribouillard-Tanvier, Déborah, et al.
Publicado: (2008)

Guanabenz (Wytensin™) selectively enhances uptake and efficacy of hydrophobically modified siRNAs
por: Osborn, Maire F., et al.
Publicado: (2015)

Guanabenz ameliorates disease in vanishing white matter mice in contrast to sephin1
por: Witkamp, Diede, et al.
Publicado: (2022)

The Antihypertensive Guanabenz Exacerbates Integrated Stress Response and Disrupts the Brain Circadian Clock
por: Lin, Hao, et al.
Publicado: (2023)

Study on the effect of EMD386088, a 5-HT(6) receptor partial agonist, in enhancing the anti-immobility action of some antidepressants in rats
por: Jastrzębska-Więsek, Magdalena, et al.
Publicado: (2017)

The histamine H(3) receptor inverse agonist pitolisant reduces body weight in obese mice
por: Kotańska, Magdalena, et al.
Publicado: (2018)

KSK-74: Dual Histamine H(3) and Sigma-2 Receptor Ligand with Anti-Obesity Potential
por: Mika, Kamil, et al.
Publicado: (2022)

Guanabenz Treatment Accelerates Disease in a Mutant SOD1 Mouse Model of ALS
por: Vieira, Fernando G., et al.
Publicado: (2015)

Guanabenz Downregulates Inflammatory Responses via eIF2α Dependent and Independent Signaling
por: Takigawa, Shinya, et al.
Publicado: (2016)

Administration of small-molecule guanabenz acetate attenuates fatty liver and hyperglycemia associated with obesity
por: Yoshino, Satoshi, et al.
Publicado: (2020)

Metabolic and Cardiovascular Benefits and Risks of EMD386088—A 5-HT(6) Receptor Partial Agonist and Dopamine Transporter Inhibitor
por: Kotańska, Magdalena, et al.
Publicado: (2017)

HBK-17, a 5-HT(1A) Receptor Ligand With Anxiolytic-Like Activity, Preferentially Activates ß-Arrestin Signaling
por: Pytka, Karolina, et al.
Publicado: (2018)

Novel serotonin 5-HT(2A) receptor antagonists derived from 4-phenylcyclohexane-5-spiro-and 5-methyl-5-phenyl-hydantoin, for use as potential antiplatelet agents
por: Czopek, Anna, et al.
Publicado: (2021)

Trace Amines and the Trace Amine-Associated Receptor 1: Pharmacology, Neurochemistry, and Clinical Implications
por: Pei, Yue, et al.
Publicado: (2016)

Guanabenz Acetate Induces Endoplasmic Reticulum Stress–Related Cell Death in Hepatocellular Carcinoma Cells
por: Kang, Hyo Jeong, et al.
Publicado: (2019)

Guanabenz Reverses a Key Behavioral Change Caused by Latent Toxoplasmosis in Mice by Reducing Neuroinflammation
por: Martynowicz, Jennifer, et al.
Publicado: (2019)

Novel and effective synthesis protocol of AgNPs functionalized using L-cysteine as a potential drug carrier
por: Wojnicki, Marek, et al.
Publicado: (2017)

High-Affinity Functional Fluorescent Ligands for Human β-Adrenoceptors
por: Mitronova, Gyuzel Y., et al.
Publicado: (2017)

Serotonin 5-HT(6) Receptor Ligands and Butyrylcholinesterase Inhibitors Displaying Antioxidant Activity—Design, Synthesis and Biological Evaluation of Multifunctional Agents against Alzheimer’s Disease
por: Więckowski, Krzysztof, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_83g2hgu48mese5no8pqprtrheo